Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDX1201-A488 in Prostate Cancer Surgery
NCT02048150Phase 1Completed
- Sponsor
- City of Hope
- Start
- Oct 2015
- Primary completion
- May 2018
- Modality
- Monoclonal Antibodies, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MDX1201-A488 in prostate cancer (PCa), sponsored by City of Hope. Primary endpoint: Imaging ability of anti-PMSA monoclonal antibody MDX1201-A488 at 1 year. Started Oct 2015; status: completed.
02
Drugs
MDX1201-A488
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02048150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02048150.